Skip to main content

Table 1 Comparison of baseline characteristics between the low-dose and conventional-dose groups

From: Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis

Characteristic Total Low-dose Conventional-dose
Number of patients 39 20 19
Age, years 34.8 ± 8.3 34.0 ± 8.7 35.6 ± 8.1
Female 39 (100.0) 20 (100.0) 19 (100.0)
Smoking
 Never 36 (92.3) 19 (95.0) 17 (89.5)
 Former 3 (7.7) 1 (5.0) 2 (10.5)
 Current 0 (0.0) 0 (0.0) 0 (0.0)
TSC 6 (15.4) 6 (30.0)* 0 (0.0)
Postmenopausal state 2 (5.1) 1 (5.0) 1 (5.3)
Previous treatment
 Medroxyprogesterone 14 (35.9) 7 (35.0) 7 (36.8)
 LHRH 4 (10.3) 1 (5.0) 3 (15.8)
 Bilateral oophorectomy 1 (2.6) 1 (5.0) 0 (0.0)
History of extrapulmonary manifestation
 Pneumothorax 24 (61.5) 15 (75.0) 9 (47.4)
 Angiomyolipoma 14 (35.9) 9 (45.0) 5 (26.3)
 Lymphangioleiomyoma 5 (12.9) 1 (5.0) 4 (21.1)
 Chylothorax 3 (7.7) 2 (10.0) 1 (5.3)
Lung function
 FEV1, % predicted 67.7 ± 26.4 62.9 ± 27.4 72.3 ± 2.3
 FVC, % predicted 86.2 ± 14.9 83.3 ± 13.8 88.9 ± 15.7
 DLco, % predicted 51.7 ± 21.8 52.6 ± 23.1 50.9 ± 21.2
 FEV1/FVC ratio 66.2 ± 20.8 64.1 ± 2 4.1 68.2 ± 17.6
6MWT
 Distance, meter 456.9 ± 103.6 458.4 ± 103.5 455.1 ± 106.9
 Initial SaO2, % 97.6 ± 1.7 97.7 ± 1.7 97.6 ± 1.7
 Lowest SaO2, % 93.7 ± 4.7 94.5 ± 4.9 92.8 ± 4.5
Sirolimus level, ng/mL 5.5 ± 2.8 3.5 ± 1.3* 7.7 ± 2.3
  1. Data are presented as mean ± SD or number (%)
  2. Abbreviations: TSC tuberous sclerosis complex, LHRH luteinising hormone-releasing hormone, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, DLco diffusing capacity of the lung for carbon monoxide, 6MWT six-minute walk test, SaO2 oxygen saturation
  3. *P < .05 (compared with conventional-dose group)